JP2024513958A5 - - Google Patents
Info
- Publication number
- JP2024513958A5 JP2024513958A5 JP2023562568A JP2023562568A JP2024513958A5 JP 2024513958 A5 JP2024513958 A5 JP 2024513958A5 JP 2023562568 A JP2023562568 A JP 2023562568A JP 2023562568 A JP2023562568 A JP 2023562568A JP 2024513958 A5 JP2024513958 A5 JP 2024513958A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- natural killer
- population
- combination
- killer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172423P | 2021-04-08 | 2021-04-08 | |
| US63/172,423 | 2021-04-08 | ||
| US202163290361P | 2021-12-16 | 2021-12-16 | |
| US63/290,361 | 2021-12-16 | ||
| PCT/US2022/023691 WO2022216837A1 (en) | 2021-04-08 | 2022-04-06 | Treatment of cancer with nk cells and an egfr targeted antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513958A JP2024513958A (ja) | 2024-03-27 |
| JP2024513958A5 true JP2024513958A5 (enExample) | 2025-04-14 |
Family
ID=83546563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562568A Pending JP2024513958A (ja) | 2021-04-08 | 2022-04-06 | Ｎｋ細胞およびｅｇｆｒ標的抗体を用いた癌治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240366664A1 (enExample) |
| EP (1) | EP4319772A4 (enExample) |
| JP (1) | JP2024513958A (enExample) |
| KR (1) | KR20240024049A (enExample) |
| CN (1) | CN118103048A (enExample) |
| AU (1) | AU2022253889A1 (enExample) |
| WO (1) | WO2022216837A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| KR102774451B1 (ko) | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| AU2019381526B2 (en) | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
| WO2024177432A1 (ko) * | 2023-02-24 | 2024-08-29 | 주식회사 엔케이맥스 | 항-egfr 항체의약품과 병용하는 자연살해세포의 tkis 내성 비소세포폐암 치료방법 |
| KR20250166262A (ko) * | 2023-03-24 | 2025-11-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 향상된 항종양 기억 반응을 갖는 조작된 자연 살해 세포 |
| WO2025191139A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567049A4 (en) * | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| WO2019179390A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/egfr antibody molecules |
| AU2019271146A1 (en) * | 2018-05-14 | 2020-12-10 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
-
2022
- 2022-04-06 CN CN202280041522.9A patent/CN118103048A/zh active Pending
- 2022-04-06 US US18/285,648 patent/US20240366664A1/en active Pending
- 2022-04-06 WO PCT/US2022/023691 patent/WO2022216837A1/en not_active Ceased
- 2022-04-06 EP EP22785379.3A patent/EP4319772A4/en active Pending
- 2022-04-06 AU AU2022253889A patent/AU2022253889A1/en not_active Abandoned
- 2022-04-06 KR KR1020237038629A patent/KR20240024049A/ko not_active Withdrawn
- 2022-04-06 JP JP2023562568A patent/JP2024513958A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513958A5 (enExample) | ||
| Shimasaki et al. | NK cells for cancer immunotherapy | |
| JP2024513522A5 (enExample) | ||
| Pistoia et al. | Human γδ T-cells: from surface receptors to the therapy of high-risk leukemias | |
| JP2024513514A5 (enExample) | ||
| Sato et al. | Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes | |
| Vuckovic et al. | Bone marrow transplantation generates T cell–dependent control of myeloma in mice | |
| Rossi et al. | Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells | |
| JP2024515169A5 (enExample) | ||
| van Ostaijen-ten Dam et al. | Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential | |
| JP2007527245A (ja) | レギュラトリーｔ細胞並びに免疫療法及び自己免疫応答の抑制におけるそれらの使用 | |
| KR20140092298A (ko) | 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도 | |
| JPH09510456A (ja) | 同種リンパ球による癌の免疫療法 | |
| Giang et al. | Nanoparticles engineered as artificial antigen-presenting cells induce human CD4+ and CD8+ Tregs that are functional in humanized mice | |
| KR20220031541A (ko) | 항-bcma car t 세포의 제조 | |
| CN115137752A (zh) | 用于干细胞移植的方法 | |
| PT2613801T (pt) | Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma | |
| Nakasone et al. | Therapeutic benefits targeting B-cells in chronic graft-versus-host disease | |
| Parisi et al. | The more, the better:“do the right thing” for natural killer immunotherapy in acute myeloid leukemia | |
| Bader et al. | Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells | |
| TW202328436A (zh) | 具有減弱之TGF-β受體傳訊的工程化T細胞 | |
| JP2021516666A (ja) | 前立腺がん特異的髄浸潤リンパ球およびその使用 | |
| AU2023257377A1 (en) | Allogeneic t cells for treatment of hematological malignancies | |
| Plaugher et al. | Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer | |
| JP2022023136A5 (enExample) |